SLC22A1 Genotype (Pro341Leu)

If you take metformin for diabetes, are on imatinib for leukemia, or use other medications that depend on liver uptake, this single inherited variant can shape how some of those drugs behave. The gene it sits in, SLC22A1, builds the doorway your liver uses to pull certain medications out of your blood. The catch is that this particular variant slows the doorway for some substrates more than others, so the clinical picture is genuinely mixed.

This test reads a fixed letter of your DNA at one position in the SLC22A1 (solute carrier family 22 member 1) gene. The result does not change over your lifetime. What it tells you is whether you were born with a version of a liver transporter called OCT1 (organic cation transporter 1) that has reduced activity for a specific subset of its substrates, and that knowledge can add context to how you and your clinician approach several medications.

What This Variant Actually Does

SLC22A1 builds OCT1, a protein that sits on the surface of liver cells and acts like a doorway, pulling certain medications and natural compounds from the blood into the liver. The c.1022C>T change swaps one amino acid for another at position 341 in this protein, a substitution called Pro341Leu (p.Pro341Leu). Lab studies show the doorway still forms and reaches the cell surface, but its activity is substrate-specific: transport of model compounds like MPP+ and TEA is reduced to roughly 65% of the normal version, while transport of metformin in the same experimental systems is preserved.

The reason this matters is that OCT1 handles a long list of medications and body compounds. It transports certain beta-blockers like metoprolol, opioids like morphine and tramadol, antiemetics like ondansetron and tropisetron, the B vitamin thiamine, and acylcarnitines, which are intermediate products of how your body burns fat for energy. It also moves the neurotransmitters serotonin, dopamine, and norepinephrine. Pro341Leu does not slow every one of these substrates equally, which is why interpretation requires looking at each drug individually rather than assuming a blanket effect.

Metformin and Type 2 Diabetes

Metformin only works once it gets inside liver cells, and OCT1 is one of its main ways in. As a class, reduced-function SLC22A1 variants have been linked in systematic reviews to differences in metformin's blood concentrations, the area under its concentration-time curve, and how much HbA1c (hemoglobin A1c, a three-month average of blood sugar) actually drops on treatment.

Pro341Leu is a more nuanced case. In vitro studies have shown that this specific variant does not significantly reduce metformin uptake, even though it does reduce transport of other OCT1 substrates. A clinical study in Korean subjects found only a non-significant trend toward higher metformin bioavailability in carriers. So while the broader SLC22A1 story is relevant to metformin response, pinning a stubborn HbA1c specifically on Pro341Leu is not well-supported by current functional data. The variant is best read as one piece of context, not as a clear explanation for metformin underperformance on its own.

Imatinib and Chronic Myeloid Leukemia

Whether OCT1 is the route imatinib uses to enter leukemic cells is actually contested. Multiple clinical studies have linked OCT1 expression or activity to imatinib response, and SLC22A1 variants have been associated with slower molecular remission in some chronic myeloid leukemia cohorts. On the other hand, a rigorous study by Nies and colleagues using multiple model systems found that imatinib uptake into cells is independent of OCT1, and that CML cell lines express neither OCT1 mRNA nor protein. If you are on imatinib and your response is not tracking as expected, your OCT1 genotype is one input your oncologist may weigh, but it should not be treated as a settled explanation.

Other Medications That Travel Through This Doorway

OCT1 transports a wide range of drugs beyond metformin. Reviews of OCT1 pharmacology describe its role for oxaliplatin, certain antivirals, the cardiovascular drug metoprolol, opioids like morphine and tramadol, and antiemetics like tropisetron and ondansetron. A reduced-function variant can shift how some of these are cleared, though, as the metformin example shows, the effect on a given drug is substrate-specific. Whether the variant matters for a particular medication depends on the drug, the dose, and the other transporters and enzymes involved.

Metabolic Signals Beyond Drugs

OCT1 also handles acylcarnitines, which are byproducts of how your cells break down fat for fuel. A genome-wide fine-mapping study connected SLC22A1 variants, including Pro341Leu, to serum acylcarnitine levels and demonstrated OCT1's role in hepatic acylcarnitine efflux. Higher circulating acylcarnitines have been linked in other research to insulin resistance and cardiovascular risk. The size of any personal effect from carrying this single variant is uncertain, but it is one mechanism by which an altered OCT1 doorway might nudge metabolic chemistry.

How Common This Variant Is

The Pro341Leu variant was reported at an allele frequency of about 16.8% in a Japanese population sample, making it more frequent in East Asian ancestry than in some other groups. Across the wider OCT1 transporter, loss-of-function alleles vary dramatically by ancestry. Roughly 9% of people of European ancestry carry a loss-of-function OCT1 allele, while up to 80% of native South American Indian populations lack fully functional OCT1. Most East Asian and Oceanian populations retain functional OCT1 overall, with this specific variant being one of the exceptions to watch for.

One-Time Result, Lifetime Use

This test reads a fixed letter of your DNA. Your result will be the same next year, in ten years, and at every doctor's visit for the rest of your life. There is no need to retest unless a confirmatory method is warranted because of an ambiguous call or a clinically inconsistent result. The value comes from integrating the result into medication decisions over decades.

What does need ongoing tracking are the downstream phenotypes that depend on liver and metabolic function. If you are on metformin, that means HbA1c, fasting glucose, and kidney function checked at least annually, and more frequently while you are adjusting therapy. If you are on imatinib, that means molecular response monitoring on the schedule your oncologist sets. The genotype adds context, not a substitute for watching how the drug actually performs.

When This Result Can Be Misleading

Genetic tests have a different set of pitfalls than blood biomarkers. The most relevant ones for this variant:

• Panel coverage limits: this assay only reads the c.1022C>T position. SLC22A1 has more than a thousand documented polymorphisms, and several other reduced-function variants (M420del, R61C, M408V) can sit on the same gene and compound the effect. A clean result here does not rule out other OCT1 variants.
• Substrate-specific effects: Pro341Leu reduces transport of some OCT1 substrates more than others, so a positive result is not a uniform signal that every OCT1-handled drug will behave differently. Each medication has to be considered individually.
• Ancestry context: variant frequencies and the surrounding variants on your chromosome vary by ancestry. The clinical meaning of a Pro341Leu result is best interpreted alongside knowledge of your background.
• Standard pharmacogenetic panels usually exclude SLC22A1: many common 12 to 14 gene panels (covering CYP enzymes, SLCO1B1, TPMT, and others) do not include this gene. A normal result on a standard pharmacogenetic panel does not mean OCT1 has been checked.
• Clinical-grade versus direct-to-consumer reports: a SNP chip result from a consumer test may flag this position but should be confirmed by a clinical-grade method before guiding medication decisions.

What Carrying the Variant Does and Does Not Mean

Carrying a reduced-function OCT1 variant raises the possibility that certain drugs will behave differently, but it does not guarantee a problem. The functional effect is substrate-specific, and many people with this variant respond fine to medications that depend on OCT1. The variant adds context to the picture, not a verdict on outcome.

It is also not a disease marker. Pro341Leu does not cause diabetes, cancer, or any other illness on its own. It only becomes clinically relevant when you take a medication for which OCT1 transport is meaningful, or when patterns in your metabolic chemistry suggest the transporter is contributing.

Decision Pathway for an Out-of-Pattern Result

If your result shows you carry the variant, the next steps depend on what medications you take or are likely to take. For someone on metformin with a stubborn HbA1c, the variant alone does not explain non-response, since functional data suggest metformin transport is preserved with Pro341Leu. The workup should still include the usual considerations of adherence, dose, kidney function, and whether combination therapy or alternative agents (such as SGLT2 inhibitors or GLP-1 receptor agonists) are appropriate. For someone on imatinib with a slower-than-expected molecular response, the OCT1 result is one input your oncologist can weigh alongside drug levels, adherence, and the broader debate about how much OCT1 actually contributes to imatinib uptake.

For someone not currently on any OCT1 substrate, the action is simpler: keep the result in your medical record, mention it whenever a new prescription is written, and share it with biological relatives, who have a meaningful chance of carrying it too. Companion testing of a broader pharmacogenetic panel can be worth considering if you take multiple chronic medications, because OCT1 is rarely the only transporter that matters. A referral to a clinical pharmacist or genetic counselor is reasonable if your medication list is complex or if you want help interpreting the result in the context of your full pharmacogenetic profile.